/ Lupin Receives USFDA Approval For Generic Benicar Tablets ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Friday, 28 April 2017

Pharma major, Lupin Limited, on Friday announced that it has received final approval for its Olmesartan Medoxomil tablets, 5 mg, 20 mg and 40 mg from the United States Food and Drug Administration (USFDA), to market generic version of Benicar tablets, 5 mg, 20 mg and 40 mg.

Lupin’s Olmesartan Medoxomil tablets, 5 mg, 20 mg and 40 mg are the AB rated generic equivalent of Daiichi Sankyo Inc.’s Benicar tablets. It is indicated for the treatment of hypertension, either alone or with other antihypertensive agents, to lower blood pressure.

Benicar tablets has US sales of USD 1,036 million (IMS MAT December 2016).

Lupin Limited is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717